Ipca Laboratories FY27 outlook: 22-23% margins post Unichem

Why Ipca’s FY27 guidance and Unichem matter

Ipca Laboratories has closed FY26 with steady top-line growth and improved profitability, and management is positioning FY27 as a step-up year. The focus is on a higher operating margin band and faster revenue growth, with domestic formulations, improving API demand, and a wider export portfolio cited as growth drivers. A key swing factor remains Unichem Laboratories, where integration work has weighed on profitability but is expected to ease as one-off costs normalise. The market is also assessing whether Ipca’s valuation reflects that earnings path, with the stock cited as trading at around 30 times FY27 estimated earnings. Alongside operating performance, investors are tracking the mechanics of the Unichem acquisition, regulatory clearances, and how quickly synergy benefits appear in reported numbers.

FY26 snapshot: revenue up, margin expands

Ipca ended FY26 on what it described as a positive note. Revenue rose 8% year-on-year to ₹9,646 crore in FY26. Operating profitability improved as the EBITDA margin expanded to 20.5% from 19.3% in FY25. The margin improvement is important because it sets a higher base for FY27 guidance and frames the impact of integration costs associated with Unichem. Management’s commentary suggests the company expects the factors that supported FY26 performance to continue, while also expecting incremental help from Unichem as restructuring and technology-transfer work tapers.

FY27 guidance: 12-13% growth and 22-23% EBITDA margin

For FY27, management has guided for 12-13% revenue growth and an EBITDA margin of 22-23%. The company has attributed the expected growth to domestic formulations, improving API demand, and a broader export portfolio. If delivered, this would represent a further margin expansion from FY26’s 20.5% and would imply better operating leverage as integration costs reduce. Management has also flagged that improvement in Unichem’s profitability could be a key contributor to the margin trajectory.

Unichem integration: the margin swing factor

Unichem’s integration has been cited as a drag on profitability in the recent past, but the company expects this to reverse as the cost profile normalises. Management expects Unichem’s EBITDA margin to reach 12-13% in FY27, up from about 8% currently. This improvement is expected to come from a combination of operational changes and the completion of large parts of integration and restructuring work. In Q4FY26 alone, Unichem incurred an additional ₹10-12 crore of R&D and technology-transfer expenses. Ipca’s view is that as these costs normalise, earnings should improve.

Ireland facility closure and estimated annual savings

A specific operational change highlighted by management is the closure of Unichem’s manufacturing facility in Ireland, with production shifted to India. Ipca estimates the move will generate annual savings of ₹40-50 crore. The company has also stated that a large part of the integration, technology transfer, and restructuring costs have already been incurred. This matters for FY27 because it links the margin guidance to identifiable cost actions and an expected reduction in exceptional or transitional expenses.

Acquisition updates: stake purchases, CCI approval, and open offer

Ipca has provided multiple updates on the Unichem transaction across announcements and filings. The Competition Commission of India (CCI) approved Ipca Laboratories’ proposed 59.38% stake purchase in Unichem Laboratories. Ipca later said it completed the acquisition of a 33.38% stake in Unichem for ₹945.35 crore, buying 2,35,01,440 equity shares at ₹402.25 per share, as per a regulatory filing.

Separately, Ipca has also disclosed open-offer terms to acquire up to an additional 26% of Unichem’s fully diluted outstanding equity share capital at ₹440 per share, aggregating to ₹805.44 crore. In another update, Ipca said it acquired an additional 19.29% stake in Unichem through an open offer for ₹597.5 crore, taking its shareholding to 52.67%, making Unichem a subsidiary. Earlier, Ipca had announced it entered a definitive share purchase agreement (SPA) on April 24, 2023 for the acquisition of 33.38% in an all-cash deal aggregating to ₹1,034.06 crore, with the purchase price also referenced at ₹440 per share in that communication.

Ipca’s investor messaging: monetisation options and near-term targets

In a conference call referenced alongside the acquisition, Ipca highlighted potential monetisation levers to address investor concerns. These included the possible monetisation of Unichem’s 3.5 acres of land in Jogeshwari, Mumbai, and a GST refund of ₹280 crore. The company also guided to deliver 16-17% revenue growth with ₹170-180 crore revenue and ₹30 crore EBITDA within two years of the acquisition, as stated in the provided information.

Another investor call hosted by DAM Capital Advisors discussed the strategic rationale, including enabling Ipca’s re-entry into the US generics market and potential cross-selling synergies in exports. That note also highlighted industry constraints, including increased competition in oral solids in the US generics market and the point that there were no USFDA inspections at Unichem sites since Feb’20, as mentioned in the call summary.

Key numbers at a glance

Deal structure and consideration: what has been disclosed

Valuation and what investors are watching

The stock has been described as trading at around 30 times FY27 estimated earnings, with commentary that the valuation seems reasonable relative to earnings potential over the next few years. The market’s near-term focus is likely to remain on whether the FY27 margin guidance of 22-23% is achieved and how much of that is attributable to Unichem’s improvement versus the core business. Progress on cost savings from the Ireland facility closure and evidence that the elevated Q4FY26 integration expenses are fading will also be key reference points. Separately, investors will track how the Unichem asset monetisation options and the cited GST refund translate into cash flow support, based on future disclosures.

Conclusion

Ipca’s FY26 numbers show a business with improving margins, and FY27 guidance points to a further step-up in profitability and growth. The Unichem integration remains central to that outlook, with specific actions like the Ireland facility closure, expected cost savings, and a reduction in one-off technology-transfer expenses. On the transaction side, disclosures cover CCI clearance, promoter stake purchases, open-offer terms, and the increase in Ipca’s holding that makes Unichem a subsidiary. The next set of updates investors will look for are concrete evidence of Unichem margin improvement, synergy execution, and the normalisation of integration costs in reported quarterly results.